Emerging challenges in ligand discovery: new opportunities for chromatographic assay

References

• Meyer AL. Prospects and challenges of developing new agents for tough Gram-negatives. Curr. Opin. Pharmacol. 5(5), 490–494 (2005).
   PubMedGoogle Scholar
• Nwaka S. Drug discovery and beyond: the role of public–private partnerships in improving access to new malaria medicines. Trans. R Soc. Trop. Med. Hyg. 99(Suppl. 1), S20–S29 (2005).
   Google Scholar
• Betz UA. How many genomics targets can a portfolio afford? Drug Discov. Today 10(15), 1057–1063 (2005).
   PubMed Web of Science ®Google Scholar
• Verkman AS. Drug discovery in academia. Am. J. Physiol. Cell Physiol. 286(3), C465–C474 (2004).
   PubMed Web of Science ®Google Scholar
• Posner BA. High-throughput screening-driven lead discovery: meeting the challenges of finding new therapeutics. Curr. Opin. Drug Discov. Devel. 8(4), 487–494 (2005).
   PubMed Web of Science ®Google Scholar
• Ganter B, Tugendreich S, Pearson CI et al. Development of a large-scale chemogenomics database to improve drug candidate selection and to understand mechanisms of chemical toxicity and action. J. Biotechnol. 119(3), 219–244 (2005).
   PubMed Web of Science ®Google Scholar
• Fitzgerald K. RNAi versus small molecules: different mechanisms and specificities can lead to different outcomes. Curr. Opin. Drug Discov. Devel. 8, 557–566 (2005).
   PubMedGoogle Scholar
• Bartz S, Jackson AL. How will RNAi facilitate drug development? Sci. STKE 2005(295), pe39 (2005).
   PubMedGoogle Scholar
• Mitchison TJ. Towards a pharmacological genetics. Chem. Biol. 1(1), 3–6 (1994).
   Google Scholar
• Mitchison TJ, Salmon ED. Mitosis: a history of division. Nature Cell Biol. 3(1), E17–E21 (2001).
   PubMed Web of Science ®Google Scholar
• Haggarty SJ, Koeller KM, Wong JC, Butcher RA, Schreiber SL. Multidimensional chemical genetic analysis of diversity-oriented synthesis-derived deacetylase inhibitors using cell-based assays. Chem. Biol. 10(5), 383–396 (2003).
   PubMed Web of Science ®Google Scholar
• Koeller KM, Haggarty SJ, Perkins BD et al. Chemical genetic modifier screens: small molecule trichostatin suppressors as probes of intracellular histone and tubulin acetylation. Chem. Biol. 10(5), 397–410 (2003).
   PubMed Web of Science ®Google Scholar
• Rininsland F, Stankewicz C, Weatherford W, McBranch D. High-throughput kinase assays with protein substrates using fluorescent polymer superquenching. BMC Biotechnol. 5(1), 16 (2005).
   Google Scholar
• Toledo-Sherman L, Deretey E, Slon-Usakiewicz JJ et al. Frontal affinity chromatography with MS detection of EphB2 tyrosine kinase receptor. 2. Identification of small-molecule inhibitors via coupling with virtual screening. J. Med. Chem. 48(9), 3221–3230 (2005).
   Google Scholar
• Hirai H, Kawanishi N, Iwasawa Y. Recent advances in the development of selective small molecule inhibitors for cyclin-dependent kinases. Curr. Top. Med. Chem. 5(2), 167–179 (2005).
   PubMed Web of Science ®Google Scholar
• Griffin RJ, Fontana G, Golding BT et al. Selective benzopyranone and pyrimido [2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and radiosensitization of a human tumor cell line in vitro. J. Med. Chem. 48(2), 569–585 (2005).
   Google Scholar
• Chuaqui C, Deng Z, Singh J. Interaction profiles of protein kinase-inhibitor complexes and their application to virtual screening. J. Med. Chem. 48(1), 121–133 (2005).
   PubMed Web of Science ®Google Scholar
• Schuffenhauer A, Ruedisser S, Marzinzik AL et al. Library design for fragment based screening. Curr. Top. Med. Chem. 5(8), 751–762 (2005).
   PubMed Web of Science ®Google Scholar
• Patterson DE, Cramer RD, Ferguson AM, Clark RD, Weinberger LE. Neighborhood behavior: a useful concept for validation of ‘molecular diversity’ descriptors. J. Med. Chem. 39(16), 3049–3059 (1996).
   PubMed Web of Science ®Google Scholar
• Clardy J, Walsh C. Lessons from natural molecules. Nature 432(7019), 829–837 (2004).
   PubMed Web of Science ®Google Scholar
• Clark AM. Natural products as a resource for new drugs. Pharm. Res. 13(8), 1133–1144 (1996).
   PubMed Web of Science ®Google Scholar
• Ortholand JY, Ganesan A. Natural products and combinatorial chemistry: back to the future. Curr. Opin. Chem. Biol. 8(3), 271–280 (2004).
   PubMed Web of Science ®Google Scholar
• Ye XS, Wong CH. Anomeric reactivity-based one-pot oligosaccharide synthesis: a rapid route to oligosaccharide libraries. J. Org. Chem. 65(8), 2410–2431 (2000).
   PubMed Web of Science ®Google Scholar
• Sweetnam PM, Price CH, Ferkany JW. Burger’s Medicinal Chemistry and Drug Discovery. Principles and Practice. Vol. 1. Wolff ME (Ed.), John Wiley & Sons, NY, USA 349–397 (1995).
   Google Scholar
• Hill DC. Trends in development of high-throughput screening technologies for rapid discovery of novel drugs. Curr. Opin. Drug Discov. Devel. 1(1), 92–97 (1998).
   Google Scholar
• Hage DS. Affinity chromatography: a review of clinical applications. Clin. Chem. 45(5), 593–615 (1999).
   PubMed Web of Science ®Google Scholar
• Lewis LM, Engle LJ, Pierceall WE, Hughes DE, Shaw K. Affinity capillary electrophoresis analyses of protein–protein interactions in target-directed drug discovery. Methods Mol. Biol. 261, 187–198 (2004).
   Google Scholar
• Guiochon G, Shirazi SG, Katti AM. Fundamentals of Preparative and Nonlinear Chromatography. Academic Press, The Netherlands (1994).
   Google Scholar
• Kelly MA, Liang H, Sytwu II et al. Characterization of SH2-ligand interactions via library affinity selection with mass spectrometric detection. Biochemistry 35(36), 11747–11755 (1996).
   Google Scholar
• Cancilla MT, Leavell MD, Chow J, Leary JA. Mass spectrometry and immobilized enzymes for the screening of inhibitor libraries. Proc. Natl Acad. Sci. USA 97(22), 12008–12013 (2000).
   PubMed Web of Science ®Google Scholar
• Geoghegan KF, Kelly MA. Biochemical applications of mass spectrometry in pharmaceutical drug discovery. Mass Spectrom. Rev. 24(3), 347–366 (2005).
   PubMed Web of Science ®Google Scholar
• Siegel MM. Early discovery drug screening using mass spectrometry. Curr. Top. Med. Chem. 2(1), 13–33 (2002).
   PubMedGoogle Scholar
• Nedelkov D, Nelson RW. Surface plasmon resonance mass spectrometry: recent progress and outlooks. Trends Biotechnol. 21(7), 301–305 (2003).
   PubMed Web of Science ®Google Scholar
• Sünksen CP, Markgren P-O, Danielson UH, Hämäläinen MD, Jansson O, Roepstorff P. Capture and analysis of low molecular weight ligands by surface plasmon resonance combined with mass spectrometry. Eur. J. Mass Spectrom. 7, 385–391 (2001).
   Google Scholar
• Hage DS, Nelson MA. Chromatographic immunoassays. Anal. Chem. 73(7), 199A–205A (2001).
   Google Scholar
• Jozwiak K, Haginaka J, Moaddel R, Wainer IW. Displacement and nonlinear chromatographic techniques in the investigation of interaction of noncompetitive inhibitors with an immobilized α3β4 nicotinic acetylcholine receptor liquid chromatographic stationary phase. Anal. Chem. 74(18), 4618–4624 (2002).
   PubMed Web of Science ®Google Scholar
• Lu L, Leonessa F, Clarke R, Wainer IW. Competitive and allosteric interactions in ligand binding to P-glycoprotein as observed on an immobilized P-glycoprotein liquid chromatographic stationary phase. Mol. Pharmacol. 59(1), 62–68 (2001).
   PubMed Web of Science ®Google Scholar
• Moaddel R, Wainer IW. Immobilized nicotinic receptor stationary phases: going with the flow in high-throughput screening and pharmacological studies. J. Pharm. Biomed. Anal. 30(6), 1715–1724 (2003).
   Google Scholar
• Moaddel R, Jozwiak K, Whittington K, Wainer IW. Conformational mobility of immobilized α3β2, α3β4, α4β2, and α4β4 nicotinic acetylcholine receptors. Anal. Chem. 77(3), 895–901 (2005).
   Google Scholar
• Moaddel R, Cloix JF, Ertem G, Wainer IW. Multiple receptor liquid chromatographic stationary phases: the co-immobilization of nicotinic receptors, γ-amino-butyric acid receptors, and N-methyl D-aspartate receptors. Pharma. Res. 19(1), 104–107 (2002).
   Google Scholar
• Kaur S, McGuire L, Tang D, Dollinger G, Huebner V. Affinity selection and mass spectrometry-based strategies to identify lead compounds in combinatorial libraries. J. Protein Chem. 16(5), 505–511 (1997).
   Google Scholar
• Huyer G, Kelly J, Moffat J et al. Affinity selection from peptide libraries to determine substrate specificity of protein tyrosine phosphatases. Anal. Biochem. 258(1), 19–30 (1998).
   Google Scholar
• Annis DA, Nazef N, Chuang CC, Scott MP, Nash HM. A general technique to rank protein–ligand binding affinities and determine allosteric versus direct binding site competition in compound mixtures. J. Am. Chem .Soc. 126(47), 15495–15503 (2004).
   PubMed Web of Science ®Google Scholar
• Annis DA, Athanasopoulos J, Curran PJ et al. An affinity selection-mass spectrometry method for the identification of small molecule ligands from self-encoded combinatorial libraries. Discovery of a novel antagonist of E. coli dihydrofolate reductase. Int. J. Mass Spectrom. 238, 77–83 (2004).
   Google Scholar
• Kasai K, Oda YJ. Frontal affinity chromatography: theory for its application to studies on specific interaction of biomolecules. J. Chromatogr. 376, 33–47 (1986).
   PubMed Web of Science ®Google Scholar
• Schriemer DC, Yalcin T, Li L. Micro-scale frontal affinity chromatography with mass spectrometric detection: a new method for the screening of compound libraries. Angew Chem. Int. Ed. 37(24), 3387–3388 (1998).
   Google Scholar
• Schriemer DC. Biosensor alternative: frontal affinity chromatography. Anal. Chem. 76(23), 440A–448A (2004).
   PubMed Web of Science ®Google Scholar
• Chan NW, Lewis DF, Rosner PJ, Kelly MA, Schriemer DC. Frontal affinity chromatography-mass spectrometry assay technology for multiple stages of drug discovery: applications of a chromatographic biosensor. Anal. Biochem. 319(1), 1–12 (2003).
   Google Scholar
• Chan NW, Lewis DF, Hewko S, Hindsgaul O, Schriemer DC. Frontal affinity chromatography for the screening of mixtures. Comb. Chem. High Throughput Screen. 5(5), 395–406 (2002).
   Google Scholar
• Slon-Usakiewicz JJ, Dai JR, Ng W et al. Global kinase screening. Applications of frontal affinity chromatography coupled to mass spectrometry in drug discovery. Anal. Chem. 77(5), 1268–1274 (2005).
   PubMed Web of Science ®Google Scholar
• Leitao A, Li M, Rodrigues A. The role of intraparticle convection in protein adsorption by liquid chromatography using POROS 20 HQ/M particles. Biochem. Eng. J. 11, 33–48 (2002).
   Google Scholar
• Winzor DJ, Sawyer WH. Quantitative Characterization of Ligand Binding. John Wiley & Sons, NY, USA (1995).
   Google Scholar
• Soltes L, Mach M. Estimation of drug–protein binding parameters on assuming the validity of thermodynamic equilibrium. J. Chromatogr. B 768, 113–119 (2002).
   PubMedGoogle Scholar
• Chen J, Hage DS. Quantitative analysis of allosteric drug–protein binding by biointeraction chromatography. Nature Biotechnol. 22(11), 1445–1448 (2004).
   PubMed Web of Science ®Google Scholar
• Tweed SA, Loun B, Hage DS. Effects of ligand heterogeneity in the characterization of affinity columns by frontal analysis. Anal. Chem. 69(23), 4790–4798 (1997).
   Google Scholar
• Slon-Usakiewicz JJ, Ng W, Dai JR, Pasternak A, Redden PR. Frontal affinity chromatography with MS detection (FAC-MS) in drug discovery. Drug Discov. Today 10(6), 409–416 (2005).
   Google Scholar
• Gottschalk I, Li YM, Lundahl P. Chromatography on cells: analyses of solute interactions with the glucose transporter Glut1 in human red cells adsorbed on lectin-gel beads. J. Chromatogr. B Biomed. Sci. Appl. 739(1), 55–62 (2000).
   PubMedGoogle Scholar
• Hodgson RJ, Chen Y, Zhang Z et al. Protein-doped monolithic silica columns for capillary liquid chromatography prepared by the sol-gel method: applications to frontal affinity chromatography. Anal. Chem. 76(10), 2780–2790 (2004).
   PubMed Web of Science ®Google Scholar
• Kovarik P, Hodgson RJ, Covey T, Brook MA, Brennan JD. Capillary-scale frontal affinity chromatography/MALDI tandem mass spectrometry using protein-doped monolithic silica columns. Anal. Chem. 77(10), 3340–3350 (2005).
   Google Scholar
• Ng ES, Yang F, Kameyama A, Palcic MM, Hindsgaul O, Schriemer DC. High throughput screening for enzyme inhibitors using frontal affinity chromatography with liquid chromatography and mass spectrometry. Anal. Chem. 77(19), 6125–6133 (2005).
   PubMed Web of Science ®Google Scholar
• Koehn FE, Carter GT. The evolving role of natural products in drug discovery. Nature Rev. Drug Discov. 4(3), 206–220 (2005).
   PubMed Web of Science ®Google Scholar
• Carr RA, Congreve M, Murray CW, Rees DC. Fragment-based lead discovery: leads by design. Drug Discov. Today 10(14), 987–992 (2005).
   PubMed Web of Science ®Google Scholar